Business Wire

GIGA Carbon Neutrality Inc. (GCN) Signs Global Strategic Partnership With Carbon Trade eXchange (CTX)

12.5.2023 07:15:00 EEST | Business Wire | Press release

Share

GIGA Carbon Neutrality Inc. (“GCN”) today announced the signing of a Strategic Partnership Agreement with London-based Carbon Trade eXchange (“CTX”) and its Australian technology parent company Global Environmental Markets (“GEM”) to globally expand CTX technology and trading.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005848/en/

CTX has launched a White Label version of its carbon market technology. The partnership agreement will enable GCN to negotiate deals with carbon trading platforms and regular stock exchanges worldwide to provide buyers spot market access to carbon credits, RECs (Renewable Energy Certificates), and offsets. Thus, an AI and blockchain-technology-powered global carbon marketplace will be created featuring carbon futures contracts based on trusted high-quality carbon credits from hundreds of projects in multiple carbon registries. These include the UNFCCC CDM Registry, Verra VCS, and Gold Standard.

GCN undertakes to support the expansion of the licensing of GEM technology infrastructure for National Carbon Meta-Registries for nations to activate their commitments under the Paris Agreement and the creation of ITMOs or voluntary carbon credits like the recently launched Global Carbon Registry (GCR) and credit standard and the recently released Core Carbon Principles by the Integrity Council for voluntary carbon markets.

CTX, GEM, and GCN will work together to expand origination of voluntary credits globally and execute larger-scale trading of the credits, bringing together the GCN business and financial network with the 15 years of experience embedded in CTX and GEM’s “Technology Infrastructure for the Future of our Planet”.

The CEO of CTX, Wayne Sharpe, stated: “The current carbon markets must scale by a factor of 10 to 100X to reduce CO2 emissions globally and meet the Paris Agreement targets. Current registry infrastructure is insufficient.

Stock Exchanges globally are struggling to handle the unique carbon trading requirements in the voluntary markets – which deliver the much-needed Climate Finance via Carbon Credits. CTX will supply and support the required technology – then the buyers decide ”

The CEO of GCN, Richard Martin, added that “this Strategic Partnership Agreement is a big opportunity for GCN to use its extensive network of partners, affiliates, and investors to fast track our global expansion plans with a proven set of carbon technology infrastructure”.

About Carbon Trade eXchange (CTX): CTX is the world's first and leading Voluntary Carbon Exchange trading multiple credit standards and project types with transparent wholesale pricing. Trading out of HQ in London since 2008, CTX services over 500 members in more than 50 countries worldwide with T+0 trades online 24/7/365.

About Global Environmental Markets (GEM): GEM designs and develops environmental FinTech solutions including trading platforms, exchanges, registries, and interfaces. Headquartered in Australia GEM owns the CTX technology IP plus a suite of B2B / B2C solutions.

About GIGA Carbon Neutrality Inc. (GCN): GCN is a service and product integrator in the global intelligent commercial transportation and equipment market to efficiently realize customers’ carbon neutrality goals. GCN and its partners offer vehicle equipment manufacturing, comprehensive technologies, operation platforms, energy data and carbon credit services. For more information, please visit the website: https://gigacarbonneutrality.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CTX/GEM:
Wayne Sharpe, info@ctxglobal.com, +447502229523, www.ctxglobal.com, www.gemglobal.com

GCN
Timothy Poor
Email: timothy.poor@gigacarbonneutrality.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions, expands our addressable market — more than doubling our revenue opportunity per gigawatt of delivered capacity — and allows us to scale both our offerings and the globa

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye